You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Assessment of Deep Learning Classification Methods for Parkinsonism

    SBC: AUTOMATED IMAGING DIAGNOSTICS LLC            Topic: 108

    SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. MT-125 for the Therapeutic Treatment of Glioblastoma

    SBC: MYOSIN THERAPEUTICS INC.            Topic: 102

    PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Protection of transplanted heart function by regulation of Na/K pump activity

    SBC: WR Biotech, LLC            Topic: NHLBI

    The objective of this proposal is to examine a novel technique called improved Synchronization Modulation Electric Field (i-SMEF) in the protection of donor hearts and improvement of transplanted graft functions. We will apply the i-SMEF on donor hearts during static cold storage and evaluate the transplanted graft function following heart transplantation in mice.Heart transplantation (HTx) remain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease

    SBC: CALIMETRIX LLC            Topic: NIBIB

    PROJECT SUMMARYThe overall goal of this Phase I proposal is to design and test the feasibility of novel magnetic resonance imaging (MRI) reference standards (“phantoms”) that are urgently needed for comprehensive and standardized quality assurance (QA) of quantitative MRI biomarkers of non-alcoholic fatty liver disease (NAFLD). We propose to develop 1) a quantitative MR elastography (MRE) stif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Virtual Reality Technologies for Dynamic Balance Rehabilitation in People with Stroke

    SBC: KOBUK TECHNOLOGIES LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT This project aims to quantify and establish elements of immersive virtual reality (VR) software that, when paired with treadmill training, produce balance perturbations that can be scaled to improve dynamic balance and are tolerated by people with stroke. VR continues to be used as an interactive and engaging way for clinicians to interact with patients during physical the ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Framework for mHealth App Security and Privacy Analysis

    SBC: UBITRIX INTERNATIONAL, INC.            Topic: NLM

    PROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications

    SBC: STEM PHARM, INCORPORATED            Topic: 102

    Project Summary/Abstract Glioblastoma (GBM) is the most prevalent primary brain tumor in adults with extremely poor survival rates and largely unchanged standard of care. While there are many challenges to developing better GBM treatments, one of the major challenges is the immune-suppressive environment commonly found within GBM tumors. This immune-suppressive nature results in a tumor that is no ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government